Pomalyst

Chemical Namepomalidomide
Dosage FormCapsule (oral; 1 mg, 2 mg, 3 mg, 4 mg)
Drug ClassAntineoplastics
SystemBlood
CompanyCelgene Corporation
Approval Year2013

Indication

  • In combination with dexamethasone, indicated for the treatment of adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • For the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pomalyst (pomalidomide) Prescribing Information.2021Celgene Corporation Summit, NJ
Document TitleYearSource
Multiple myeloma, version 3.2021.2020Journal of the National Comprehensive Cancer Network
Clinical practice guideline: multiple myeloma. 2019Myeloma Australia
Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.2019Journal of Clinical Oncology
AIDS-Related Kaposi Sarcoma, Version 2.2019. 2019Journal of the National Comprehensive Cancer Network
Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology